Skip to main content

FDA authorizes at-home coronavirus test that uses your spit

The Food and Drug Administration has authorized a second at-home test for the coronavirus — one that can detect the virus using saliva samples.

The test is made by a Rutgers University laboratory, RUCDR Infinite Biologics, in partnership with Spectrum Solutions and Accurate Diagnostic Labs. The Rutgers test uses a saliva collection device and must be sent back to the lab for testing. You can only receive the test if it’s been ordered through a physician.

Coronavirus is wreaking havoc on the world, and will continue to for months to come — but what exactly are we doing to fight it? Have we made any progress on a vaccine? Here’s what you need to know
coronavirus taiwan asia technology success science researcher getty

“This provides an additional option for the easy, safe, and convenient collection of samples required for testing without traveling to a doctor’s office, hospital, or testing site,” said FDA Commissioner Dr. Stephen M. Hahn in a statement.

The test costs around $100, and the lab will be able to process around 20,000 a day, according to The New York Times.

The Rutgers test is the second at-home test to get an emergency use authorization from the FDA. An authorization allows doctors and public health officials to use unapproved methods to battle a public health crisis that may have no alternatives, such as the coronavirus pandemic.

The first at-home test, from Pixel, uses a nasal swab and saline.

For the latest updates on the novel coronavirus outbreak, visit the World Health Organization’s COVID-19 page.

Editors' Recommendations

Jenny McGrath
Former Digital Trends Contributor
Jenny McGrath is a senior writer at Digital Trends covering the intersection of tech and the arts and the environment. Before…
How to sign up for a coronavirus vaccine trial
Cambridge Biotech Moderna Leads in Race For Coronavirus Vaccine

With the race to develop a coronavirus vaccine heating up, clinical studies around the U.S are looking for willing participants to help them complete various stages of their research. Tech conglomerates Moderna, AstraZeneca, Johnson & Johnson, and Novavax are all in various stages of human trials, each of which requires hundreds of volunteers. So how does one sign up for a vaccine trial?
How to sign up for a coronavirus trial
While the words "scientific trial" may bring up images of mad scientists, the average clinical study is an important part of the vaccine development process. After methods prove hopeful in laboratories, researchers then perform several detailed studies with humans, to perfect the product. To speed up trial involvement for a coronavirus vaccine, the U.S. National Institute of Health has launched an online public network that connects possible volunteers with hundreds of research facilities across the U.S.

But a lot still has to happen before scientists can stick you with a needle. Possible volunteers must be 18 years or older, and must fill out a volunteer screening history. Signing up for the database takes less than 10 minutes, and will automatically connect users with the trial closest to them.

Read more
Fauci ‘cautiously optimistic’ we will have a coronavirus vaccine this year
gloved hands holding coronavirus test tube stylized image

Dr. Anthony Fauci told a House panel he is "cautiously optimistic" that a coronavirus vaccine will be developed this year.

“We hope that as the time we get into the late fall and early winter we will have, in fact, a vaccine that we can say would be safe and effective,” Fauci, the Director of the National Institute of Allergy and Infectious Diseases, testified before a Democrat led-panel on the outbreak on Friday, July 31. “One can never guarantee the safety or effectiveness unless you do the trial, but we are cautiously optimistic.”

Read more
New coronavirus vaccine triggers immune response in early testing
medical employee holding mask stylized image

A coronavirus vaccine developed by Oxford University and drug company AstraZeneca triggered an immune response in early trials, according to a study published on Monday, July 20. 

The vaccine produced strong immune responses in patients inoculated with both single- and two-dose versions of the vaccine. The promising results were first published in the scientific journal The Lancet.

Read more